Format

Send to

Choose Destination
See comment in PubMed Commons below
Adv Ther. 2011 Mar;28 Suppl 1:11-6. doi: 10.1007/s12325-010-0102-x. Epub 2011 Mar 9.

Lenalidomide treatment for patients with multiple myeloma: diagnosis and management of most frequent adverse events.

Author information

1
Hospital Txagorritxu, Vitoria-Gasteiz, Spain.

Abstract

The introduction of novel antimyeloma therapies, including thalidomide, lenalidomide, and bortezomib, has expanded treatment options for patients with this disease. These compounds have altered the natural history of multiple myeloma, resulting in substantial improvements in patient outcomes. However, like with any other drug, their use is associated with a specific toxicity profile. The major adverse events (AEs) associated with lenalidomide include: hematological toxicities (myelosuppression), mainly neutropenia, venous thromboembolism, gastrointestinal disturbance, skin toxicity, atrial fibrillation, asthenia, and decreased peripheral blood stem cell yield during stem cell collection when lenalidomide is used after a long period of time. These AEs are predictable, consistent, and manageable with patient monitoring, supportive care, and dose adjustment. In this article, using three clinical cases as examples, we discuss the diagnoses and management of the most frequent AEs associated with lenalidomide treatment in patients with multiple myeloma.

PMID:
21431627
DOI:
10.1007/s12325-010-0102-x
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Springer
    Loading ...
    Support Center